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Abstract: Management of metastatic colorectal cancer requires a multimodal approach and 
must be performed by an experienced, multidisciplinary expert team. The optimal choice 
of the individual treatment modality, according to disease localization and extent, tumor 
biology, and patient clinical characteristics, will be one that can maintain quality of life 
and long-term survival, and even cure selected patients. This review is an overview of the 
different therapeutic approaches available in metastatic colorectal cancer, for the purpose 
of defining personalized therapeutic algorithms according to tumor biology and patient 
clinical features.
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Introduction
Approximately 20% of patients affected by colorectal cancer (CRC) present meta-
static disease in early diagnosis, while 35% of patients, treated with curative intent, 
will develop advanced disease over time.1 The prognosis of these patients is poor 
and the aims of chemotherapy are care (only in selected cases), survival prolonga-
tion, disease progression delay, quality of life improvement, tumor size reduction, 
or symptom palliation. Through available multidisciplinary therapeutic strategies 
(surgery, chemotherapy, biological agents, radiotherapy), the clinical approach to 
unresectable metastatic CRC (mCRC) should be potentially curative or palliative. 
Moreover, knowledge of both tumor biology and patient clinical features has 
allowed for the identification of four different patient classes, which correspond to 
four different therapeutic options, respectively: (1) patients with minimal disease 
that is immediately resectable (R0-resectable liver with/without lung metastases 
[group 0]); (2) patients with extensive disease that is not immediately resectable 
(potentially resectable metastatic disease after conversion chemotherapy [group 1]); 
(3) never-resectable metastatic disease in symptomatic patients whose quality of 
life and survival are compromised due to disease extension (palliation therapy 
[group 2]); and (4) never-resectable metastatic disease in asymptomatic patients 
(palliation therapy, continuum care [group 3]).2 The purpose of this review is 
to summarize the different therapeutic approaches to adopt according to patient 
clinical characteristics and tumor biomolecular features (Table 1 shows the groups 
mentioned above and related treatments) and to explain current therapeutic options 
available in mCRC.
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Table 1 First-line treatment options according to tumor biology and patient clinical features
Group Clinical presentation Treatment aim Treatment intensity KRAS wild-type KRAS mutated
0 R0-resectable liver and/or  
lung metastases
– Cure 
–  Decrease risk of  
relapse
– Nothing 
– Moderate (FOLFOX)
– –
1 Not R0-resectable liver  
or lung metastases but  
might became resectable  
after conversion CT
Maximum tumor  
shrinkage
Upfront most active 
combination regimen
FOLFiRi+cet 
FOLFOX+pan/cet 
FOLFOX/XeLOX+bev 
FOLFOXiRi 
FOLFiRi/XeLiRi+bev 
FOLFOX/XeLOX 
FOLFiRi/XeLiRi
FOLFOX/XeLOX+bev 
FOLFOXiRi 
FOLFiRi/XeLiRi+bev 
FOLFOX/XeLOX 
FOLFiRi/XeLiRi
2 Multiple metastases sites,  
with rapid progression  
and symptomatic patients
–  Clinically relevant  
tumor shrinkage  
if possible
–  At least achieve  
control of DP
Upfront active  
combination: at least  
doublet
FOLFiRi+cet 
FOLFOX+pan/cet 
FOLFOX/XeLOX+bev 
FOLFOXiRi 
FOLFiRi/XeLiRi+bev 
FOLFOX/XeLOX 
FOLFiRi/XeLiRi
FOLFOX/XeLOX+bev 
FOLFOXiRi 
FOLFiRi/XeLiRi+bev 
FOLFOX/XeLOX 
FOLFiRi/XeLiRi
3 Multiple metastases sites,  
asymptomatic patients
–  Abrogation of  
further progression
–  Tumor shrinkage  
less relevant
Sequential approach 5-FU/Lv 
Cape 
5-FU/Lv+bev 
Cape+bev 
XeLOX/FOLFOX 
FOLFiRi/XeLiRi 
cet/pan 
watchful waiting triplets  
(±bev or cet/pan)
5-FU/Lv 
Cape 
5-FU/Lv+bev 
Cape+bev 
XeLOX/FOLFOX 
FOLFiRi/XeLiRi 
FOLFOXiRi/Bev
Abbreviations: 5-FU, 5-fluorouracil; bev, bevacizumab; cape, capecitabine; cet, cetuximab; LV, leucoverin; FOLFIRI, infusional 5-FU/bolus folinic acid/irinotecan; FOLFOX, 
infusional 5-FU/bolus folinic acid/oxaliplatin; FOLFOXIRI, infusional 5-FU/bolus folinic acid/irinotecan/oxaliplatin; pan, panitumumab; DP, disease progression; XELOX, 
capecitabine/oxaliplatin; XELIRI, cape/irinotecan; CT, chemotherapy.
Surgical treatment  
of advanced disease
Surgery is feasible even in advanced disease. It is important 
to establish, in patients with unresectable mCRC and in 
whom the primary tumor has not been removed, whether or 
not the primary tumor is symptomatic; in fact, if the primary 
tumor is symptomatic (bleeding, bowel obstruction, bowel 
perforation), surgery is immediately necessary. Liver, lung, 
and ovarian metastases and primary site of disease should be 
evaluated for surgery, and surgery should be considered in all 
patients who have had an important tumoral mass reduction 
through chemotherapy. The chemotherapy should be discon-
tinued as soon as the disease becomes resectable, because 
continuation of treatment exposes patients to liver toxicity 
and surgery risks. R0-resectable liver metastases represents 
the only curative option available,3 while R1-resectable 
liver metastases is an acceptable strategy if it produces a 
significant benefit to patients.4 Currently, patients diagnosed 
with potentially resectable mCRC should undergo an upfront 
evaluation by a multidisciplinary team, including surgical 
consultation, to assess resectability status.
Management of patients with minimal  
disease (R0-resectable liver and/or lung 
metastases [group 0])
Before explaining the therapeutic approach to be taken in this 
patient group (group 0), it is necessary to clarify resectability 
criteria. The criteria for determining patient suitability for resec-
tion of metastatic disease are the likelihood of achieving complete 
resection of all evident disease with negative surgical margins 
and maintaining adequate liver reserve (.30%).4 It should be 
noted that metastasis number or size, bilobar extension disease, 
and vascular structure involvement are not contraindicative 
to resection of the tumor and its metastases. Patients with a 
single small (,2 cm) liver metastasis may be considered for 
upfront surgery and for postoperative chemotherapy with an 
infusional 5-fluorouracil (5-FU)/bolus 5-FU/leucoverin (LV)/
oxaliplatin (FOLFOX)-based regimen for an overall treatment 
of 6 months.5 For patients with up to four liver metastases, 
perioperative chemotherapy (3 months pre-chemotherapy and 
3 months post-chemotherapy with FOLFOX regimen) should 
be applied. The European Organisation for Research and Treat-
ment of Cancer 40983 trial has demonstrated an advantage in 
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progression-free survival (PFS) in patients undergoing resection 
plus chemotherapy versus resection alone (18.7 vs 11.7 months, 
respectively) and a rate of PFS at 3 years from 33.2% to 42.4% 
(hazard ratio [HR] 0.73; P = 0.025) in patients who underwent 
surgery after perioperative chemotherapy.6 Furthermore, a recent 
meta-analysis identified three randomized clinical trials compar-
ing surgery alone to surgery plus systemic perioperative therapy 
with 642 evaluable patients with CRC liver metastases. The 
pooled analysis showed a benefit of chemotherapy in PFS (HR 
0.75; P = 0.003) and disease-free survival (HR 0.71; P = 0.001), 
but not in overall survival (OS) (HR 0.74; P = 0.088).7 This 
approach represents the current standard for patients with mini-
mal and resectable disease.7 Pre- and postoperative chemotherapy 
versus postoperative chemotherapy alone, as well as the addition 
of biological agents, are being investigated in ongoing trials. In 
the new Early Presentation Of Cancer Project (EPOC) study, 
272 patients with KRAS wild-type (wt) tumor operable liver 
metastases were randomized to receive FOLFOX plus or minus 
cetuximab for 12 weeks before, then 12 weeks following, surgery. 
The new EPOC study was stopped when the futility analysis was 
predefined by a protocol. With 45.3% of the expected events 
observed, PFS was significantly worse in the cetuximab arm (14.8 
vs 24.2 months; HR 1.50; P , 0.048).8 In clinical practice, post-
operative adjuvant chemotherapy with FOLFOX/ capecitabine/
oxaliplatin (XELOX) or FOLFOX/XELOX plus bevacizumab 
is administered for an overall treatment of 6 months, despite lack 
of data favoring this approach and an unspecified chemotherapy 
duration (6 months).9 As regards treatment of lung-only metas-
tases, the issue is similar to liver metastases.10 Results from a 
retrospective analysis of 795 previously untreated mCRC patients 
randomized in a Phase III trial evaluating the efficacy of mostly 
oxaliplatin-containing chemotherapy regimens indicated that 
patients with lung-only metastases (two out of 24 patients) were 
able to undergo curative resection after treatment. The median 
OS in these patients was 42.4 months.11 Despite the lack of data 
from prospective trials regarding perioperative treatment, an 
approach similar to management of resectable liver metastases 
should be considered. Alternatively, an initial resection followed 
by postoperative adjuvant treatment with fluoropyrimidine with 
or without oxaliplatin for 6 months can be performed.10
Management of patients with extensive 
disease (potentially resectable metastatic 
disease after conversion chemotherapy 
[group 1])
The majority of patients diagnosed with metastatic colorectal 
disease have unresectable disease. However, for those with 
liver-limited unresectable disease that, because of involve-
ment of critical structures, cannot be resected unless regres-
sion is accomplished, chemotherapy is being increasingly 
considered in highly selected cases in an attempt to down-
size colorectal metastases and convert them to a resectable 
status. Usually, a doublet chemotherapy plus monoclonal 
antibody or a triplet chemotherapy is used for conversion 
chemotherapy.
Doublet chemotherapy regimens comprising infusional 
5-FU/bolus 5-FU/LV/irinotecan (FOLFIRI) or FOLFOX 
have reported that a significant portion (32.5% and 40%, 
respectively) of the patients with initially unresectable liver 
metastases undergo liver resection.12,13 Data emerging from 
randomized trials suggest that the addition of a targeted agent 
to a doublet chemotherapy might be more effective in treatment 
of liver-limited disease. In the CELIM Phase II trial, patients 
were randomized to receive cetuximab with either FOLFOX 
or FOLFIRI.14 Retrospective analysis showed that, in both 
treatment arms, combined resectability increased from 32% 
to 60% after chemotherapy in patients with KRAS wt tumor 
(P , 0.0001) with the addition of cetuximab. A recent meta-
analysis of four randomized controlled trials concluded that the 
addition of monoclonal antibody anti-epidermal growth factor 
receptor (EGFR) to chemotherapy significantly increased the 
resection rate (RR) ([R0] from 11% to 18%; odds ratio [OR] 
1.59; P = 0.04), and PFS, but not OS in patients with KRAS 
wt tumor.15 Also, bevacizumab was analyzed in this setting. 
Data seem to suggest that the combination of bevacizumab 
with an irinotecan-based regimen modestly improves the RR 
(,2%).16 On the other hand, the association of FOLFOX with 
bevacizumab showed no benefit in RR and tumor reduction 
compared with chemotherapy alone (8.4% vs 6.1%, respec-
tively).17 However, because it is not known in advance whether 
resectability will be achieved, the use of bevacizumab with 
oxaliplatin-based therapy in this setting is acceptable. In addi-
tion, infusional 5-FU/LV/oxaliplatin/irinotecan (FOLFOXIRI) 
has been compared with FOLFIRI in unresectable patients.18 
FOLFOXIRI led to an increase in R0 secondary RRs, from 
6% to 15% (P = 0.033). In a follow-up study of the Gruppo 
Oncologico Nord Ovest (GONO) trial, the 5-year survival rate 
was higher in the group receiving FOLFOXIRI (15% vs 8%), 
with a median OS of 23.4 versus 16.7 months (P = 0.026).19 
There are no available data regarding effectiveness compari-
sons between doublet chemotherapy plus bevacizumab versus 
doublet chemotherapy plus cetuximab or panitumumab in 
KRAS wt patients, but, at the same time, FOLFIRI or FOLFOX 
plus anti-EGFR antibodies appears to be more effective in 
terms of major tumor shrinkage and secondary resectability 
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than bevacizumab-based combination in potentially resectable 
patients with extensive disease. FOLFOXIRI plus bevaci-
zumab is very effective, but data about liver metastases R0 
are not yet available.20
First-line treatment  
of advanced disease
The current first-line management of disseminated mCRC 
involves various active drugs, either in combination or as 
single agents: 5-FU/LV, capecitabine, irinotecan, oxaliplatin, 
bevacizumab, cetuximab, and panitumumab. The association 
of 5-FU/LV revealed an advantage in terms of RR without 
any impact on OS.21 The doublet chemotherapy FOLFIRI and 
FOLFOX led to a considerable increase in RR and prolonged 
OS, and similar RR and PFS times were obtained when 
these regimens were used as first-line therapy.22,23 XELOX 
is comparable to FOLFOX in terms of activity and efficacy, 
while capecitabine/irinotecan (XELIRI) is burdened by severe 
gastrointestinal toxicity.24,25 FOLFOXIRI is more effective 
than FOLFIRI in terms of PFS (9.8 vs 6.9 months; HR 0.63; 
P = 0.0006) and OS (22.6 vs 16.7 months; HR 0.70; P = 0.032), 
although this regimen has to be reserved for patients with 
appropriate conditions and without relevant comorbidities.18 
Currently, conventional first-line therapy of mCRC is based 
on the association of conventional chemotherapy regimens 
and biological drugs that include bevacizumab, cetuximab, or 
panitumumab; in fact, clinical trials have shown that targeted 
agents increase the efficacy of conventional chemotherapy 
regimens.16,17,26,28–30 Bevacizumab has been shown to increase 
RR and PFS in association with all chemotherapy regimens. 
OS, however, appears to differ between the various combina-
tions of treatment; specifically, OS is greater in FOLFIRI plus 
bevacizumab regimen than FOLFOX plus bevacizumab.16,17 
Recently, the TRIplet chemotherapu plus BEvacizumab 
(TRIBE) randomized, Phase III trial has proven a statistically 
significant advantage in FOLFOXIRI plus bevacizumab treat-
ment group versus FOLFIRI plus bevacizumab in terms of 
PFS and objective response rate (ORR).20
Literature has shown that tumors with a mutation in 
codon 12 or 13 (exon 2) of the KRAS gene are essentially 
insensitive to EGFR inhibitors such as cetuximab or panitu-
mumab;26,27 it has also recently emerged that both rare KRAS 
mutations (exon 3) and NRAS mutations could invalidate the 
efficacy of panitumumab treatment.28
Cetuximab in first-line chemotherapy has shown a benefit 
in terms of PFS in patients with k-ras wt tumor; a retro-
spective analysis in this subgroup also demonstrated that 
cetuximab plus FOLFIRI gave a greater benefit in terms of 
OS than FOLFIRI alone.26 Analogously, panitumumab plus 
FOLFOX showed a statistically significant advantage in all 
RAS wt patients in terms of PFS and OS.28,29 Table 2 shows 
RR, PFS, and OS data of main mCRC first-line treatment 
clinical trials. Finally, FIRE-3 study results were presented 
during the 13th ASCO annual meeting.31 In this Phase III 
trial, 592 patients with KRAS wt tumor were randomized to 
receive FOLFIRI plus cetuximab or FOLFIRI plus bevaci-
zumab. The median duration of treatment was 4.7 months 
versus 5.3 months, respectively. The primary end point was 
RR, but the study did not meet this end point because RR 
was comparable in the two groups (62% vs 57%, OR 1.249); 
median PFS was nearly identical (10.3 vs 10.4 months; 
HR 1.04; P = 0.69); however, OS showed a significantly bet-
ter outcome in the FOLFIRI plus cetuximab group (28.8 vs 
25.0 months; HR 0.77; P = 0.0164). This study has several 
methodological limitations, therefore it does not decisively 
solve the riddle of which biological agent should be used 
in the first-line treatment of mCRC RAS wt patients.31 We 
must await the results of a Phase III study conducted by the 
CALGB group in order to have solid data about cetuximab 
versus bevacizumab in mCRC first-line treatment.32
In conclusion, the choice of which therapeutic regimen 
to use in mCRC first-line treatment is based on consideration 
of the goals of therapy and the differing toxicity profiles of 
the constituent drugs.
Management of never-resectable  
and symptomatic patients (palliation  
therapy [group 2])
The treatment aim in group 2 is rapid tumor size reduction to 
resolve symptoms related to disease extension. Either triplet 
or doublet chemotherapy can be the first choice because each 
provides the chance of fast and major response (Tables 1 and 2). 
There is no clear preference for triplet or doublet chemotherapy; 
rather, the decision is based on tumor symptoms, dynamics, 
tumor biology, and clinical patient characteristics.
Management of never-resectable  
and asymptomatic patients (continuum  
care [group 3])
For those patients without present or imminent symptoms 
and limited risk for rapid deterioration, the aim is preven-
tion of tumor progression with symptom disappearance and 
prolongation of life with minimal treatment, thus ensuring 
continuum care. Treatment is based on a single agent or dou-
blet chemotherapy with low toxicity. Of great importance is 
the data of the AVEX trial, a Phase III study conducted on 
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elderly mCRC patients that showed how the combination of 
fluoropyrimidines with bevacizumab is superior to fluoro-
pyrimidines alone.33 Initial therapy guidelines recommend 
a choice of five chemotherapy regimens: FOLFOX; FOL-
FIRI; XELOX, infusional 5-FU/LV; or capecitabine, plus 
or minus the association with a biological agent (Tables 1 
and 2).16,17,26,28,29
Maintenance treatment strategies
There are several maintenance strategies that are used in 
mCRC after effective first-line chemotherapy in order to 
reduce disease progression and treatment toxicity.
The OPTIMOX1 study showed that a stop-and-go 
approach using oxaliplatin-free intervals resulted in 
decreased neurotoxicity, but did not affect OS, in patients 
receiving FOLFOX as initial therapy for metastatic disease.34 
Therefore, adjusting the schedule and timing of the adminis-
tration of this drug can limit this adverse effect. From OPTI-
MOX1 trial results is derived another therapeutic strategy: 
reintroduction of a chemotherapeutic agent and residual 
sensitivity. In the investigational arm of the OPTIMOX1 
study, oxaliplatin was reintroduced in 40% of patients and 
achieved a disease control rate of 69%. Thus, reintroduction 
of oxaliplatin should be considered in patients who have 
an initial benefit from FOLFOX or XELOX and who can 
tolerate it.
Another study, the CONcePT trial, evaluated alternat-
ing oxaliplatin administration according to the following 
schedule: eight doses of FOLFOX plus bevacizumab followed 
by eight maintenance doses of 5-FU/LV plus bevacizumab, 
alternating the two regimens until disease progression. 
Through this stop-and-go strategy, PFS of 12 months and a 
low toxicity profile were obtained.35
In addition to conventional chemotherapeutic drugs, 
biologic agents have also been tested in mCRC maintenance 
therapy; in particular, bevacizumab has been analyzed more 
in this setting than cetuximab.
The anti-EGFR monoclonal antibody was investigated 
as a maintenance single-agent in the NORDIC VII trial, but 
results were not encouraging.36
Diaz-Rubio et al, in a Phase III trial, suggested that main-
tenance therapy with single-agent bevacizumab represented 
an appropriate option after XELOX plus bevacizumab che-
motherapy induction, on the basis of noninferiority results 
in terms of PFS obtained in a bevacizumab maintenance 
group versus a XELOX plus bevacizumab maintenance 
group (10.4 vs 9.7 months, respectively).37 At the ASCO 
13th annual meeting, two other clinical trials38,39 about the 
use of bevacizumab in first-line treatment until progression 
were presented but having, in the control arm, exclusively 
observation. The CAIRO3 study was designed to investi-
gate the efficacy of observation versus maintenance treat-
ment with capecitabine plus bevacizumab after induction 
treatment with six cycles of XELOX plus bevacizumab. 
Maintenance treatment with XELOX plus bevacizumab 
is feasible and significantly prolongs PFS; there is also a 
Table 2 RR, PFS, and OS data of main clinical trials about mCRC first-line treatment
Author Phase  
study
Treatment Population OS 
(months)
HR 
P-value
PFS 
(months)
HR 
P-value
RR 
(%)
OR 
P-value
Hurwitz  
et al16
iii iFL/placebo 
iFL/Bv 
5-FU/FA/Bv
923 15.6 
20.3 
18.3
0.66 
P , 0.001
6.2 
10.6 
8.8
0.54 
P ,0.001
34.8 
44.8 
40
P = 0.004
Saltz et al17 iii XeLOX/FOLFOX4 
XeLOX/FOLFOX+Bv
1,400 19.9 
21.3
0.89 
P = 0.0769
8.0 
9.4
0.83 
P = 0.0023
49 
47
0.90 
P = 0.31
Falcone  
et al20
iii FOLFOXiRi+Bv 
FOLFiRi+Bv
508 31.0a 
25.8a
0.83 
P = 0.125a
12.2 
9.7
0.77 
P = 0.006
65 
53
P = 0.006
van Cutsem  
et al26
iii FOLFiRi+C 
FOLFiRi
348 
(wt KRAS pts)
23.5 
20.0
P = 0.093 8.9 
8.0
0.85 
P = 0.048
46.9 
38.7
1.40 
P = 0.004
Bokemeyer  
et al30
ii FOLFOX+C 
FOLFOX
134 
(wt KRAS pts)
22.8 
18.5
0.85 
P = 0.39
7.7 
7.2
0.57 
P = 0.016
61 
37
2.54 
P = 0.19
Douillard  
et al29
iii FOLFOX+P 
FOLFOX
656 
(wt KRAS pts)
23.9 
19.7
0.83 
P = 0.072
9.6 
8.0
0.80 
P = 0.02
55 
48
1.35 
P = 0.068
Oliner et al28 iii FOLFOX+P 
FOLFOX
259 
(all wt RAS pts)
26.0 
20.0
0.78 
P = 0.04
10.1 
7.9
0.72 
P , 0.01
NR 
NR
NR
Note: aimmature data.
Abbreviations: 5-FU, 5-fluorouracil; BV, bevacizumab; C, cetuximab; P, panitumumab; FA, folinic acid; FOLFIRI, infusional 5-FU/bolus folinic acid/irinotecan; FOLFOX4, 
infusional 5-FU/bolus FA/oxaliplatin; FOLFOXIRI, infusional 5-FU/bolus FA/irinotecan/oxaliplatin; HR, hazard ratio; IFL, bolus 5-FU/FA/irinotecan; mCRC, metastatic 
colorectal cancer; NR, not reported; OR, odds ratio; OS, overall survival; PFS, progression-free survival; pts, patients; RR, response rate; wt, wild-type; XELOX, capecitabine/
oxaliplatin.
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significant difference in OS in adjustment analysis.38 In the 
noninferiority Phase III SAKK 41/06 trial, noninferiority 
of maintenance treatment with bevacizumab alone versus 
observation arm, after 4–6 months of first-line chemotherapy 
plus bevacizumab was investigated. The noninferiority in 
time to progression could not be demonstrated, although 
advantageous data for PFS were shown (9.5 months in beva-
cizumab group vs 8.5 in the observation group; P = 0.02); no 
difference in OS was observed in the two arms.39 At present, 
there are no clear data on the use of bevacizumab in the 
maintenance setting. In order to attain precise indications, 
it is necessary to wait for data from the Phase III AIO KRK 
0207 trial, which compares maintenance therapy with beva-
cizumab alone versus bevacizumab plus fluoropyrimidines 
versus observation.40
Associations between targeted agents have also been 
investigated in maintenance treatment: the GERCOR-
DREAM trial evaluated bevacizumab combined with erlotinib 
after first-line oxaliplatin- or irinotecan-based chemotherapy. 
After 31 months of follow-up, median PFS was 4.6 months in 
the bevacizumab group versus 5.8 months in the bevacizumab 
plus erlotinib group (HR 0.73; P = 0.005).41
As the maintenance strategy we reported treatment-free 
interval, which was investigated in two trials, OPTIMOX2 
and COIN.42, 43
In the Phase II OPTIMOX2 trial,42 patients were ran-
domized to receive either an OPTIMOX1 approach or an 
induction FOLFOX regimen followed by discontinuation 
of all chemotherapy until tumor progression reached base-
line, followed by reintroduction of FOLFOX. Results of 
the study showed no difference in OS for patients receiving 
the OPTIMOX1 approach compared with those undergo-
ing an early, preplanned, chemotherapy-free interval (OS 
23.8 vs 19.5 months; P = 0.42). However, the median 
duration of disease control, which was the primary end 
point of the study, reached statistical signif icance at 
13.1 months in patients undergoing maintenance therapy 
and 9.2 months in patients with a chemotherapy-free 
interval (P = 0.046).
The MRC COIN study43 compared continuous oxaliplatin-
based chemotherapy until disease progression and treatment 
holiday after 3 months of induction treatment, followed 
by chemotherapy reintroduction, on disease progression. 
Although this trial did not show noninferiority of intermittent 
compared with continuous chemotherapy in terms of OS, 
chemotherapy-free intervals remain a treatment option for 
some patients with advanced colorectal cancer, offering 
reduced time on chemotherapy, reduced cumulative toxic 
effects, and improved quality of life.
Second-line chemotherapy  
after first disease progression  
and further treatment lines
Second and further chemotherapy lines in mCRC depend on 
previous therapies. Particularly, based on clinical evidence, 
there are four different chemotherapeutic modalities to use 
after first-line disease progression. For patients who received 
an oxaliplatin-based regimen for initial therapy, FOLFIRI 
or irinotecan alone are recommended options. Usually in 
patients with KRAS wt tumor, irinotecan-based chemotherapy 
can be combined with cetuximab or panitumumab,44,45 while 
in patients with KRAS mutant tumor can be combined with 
bevacizumab46,47 or aflibercept.48 Anti-vascular endothelial 
growth factor treatment use beyond first-line bevacizumab-
based chemotherapy progression has been analyzed by the 
TML and VELOUR trials, which observed patients continu-
ing on bevacizumab or aflibercept having a modest improve-
ment in OS.47,48
For mCRC patients who received an irinotecan-based 
regimen as initial treatment, FOLFOX or XELOX alone 
or with bevacizumab,46 cetuximab or panitumumab plus 
irinotecan, or single-agent cetuximab or panitumumab 
are recommended options.44,45,49,50 In patients treated with 
5-FU/LV or capecitabine as initial therapy, options after first 
progression include FOLFOX, XELOX, FOLFIRI, single-
agent irinotecan, or irinotecan plus oxaliplatin. These can 
varyingly be combined with bevacizumab or aflibercept.46,47 
Finally, for patients who received FOLFOXIRI as initial 
therapy, cetuximab or panitumumab plus irinotecan or 
cetuximab or panitumumab alone are recommended options 
for those with KRAS wt tumor.44,45,49,50 However, regarding 
later chemotherapy lines, the possible options for patients 
with KRAS wt not previously treated with anti-EGFR anti-
bodies are cetuximab with or without irinotecan and pani-
tumumab with or without FOLFIRI.44,45,49,50 In patients who 
are refractory to 5-FU, oxaliplatin, irinotecan, anti-EGFR 
antibodies (KRAS wt tumor only), bevacizumab, and rego-
rafenib, treatment with fluoropyrimidines and mitomycin 
or reintroduction of oxaliplatin (and irinotecan) results in 
very limited improvement in some patients treated as last 
line. However, despite poor results in the data, this might be 
justified in some patients. Finally, regorafenib demonstrated 
an advantage in terms of OS versus placebo in last-line 
salvage treatment.51
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Table 3 illustrates RR, PFS, and OS data of main 
clinical trials evaluating mCRC second- and further-line 
treatments.
Conclusion
Treatment of mCRC involves the use of active cytotoxic 
drugs and biological agents, either in combination or as 
single agents. Until recently, the only biological agent with 
proven first-line efficacy was bevacizumab, but options have 
expanded from the data generated with anti-EGFR monoclo-
nal antibodies. Anti-EGFR agents can be added to first-line 
FOLFIRI or FOLFOX in patients whose tumors express RAS 
wt. These agents may improve outcomes when added to che-
motherapy, particularly in PFS and, in the case of cetuximab, 
OS and ORR. The selection of first-line therapy should be 
based on the individual treatment goals after considering the 
efficacy and tolerability of each regimen. For patients with 
metastases confined to the liver, surgical resection offers 
a potentially curative approach. For initially unresectable 
lesions, treatment regimens offering high response rates 
may produce sufficient tumor shrinkage to permit complete 
resection. Regimens with high response rates are also prefer-
able for patients requiring symptom relief or for those with 
large tumor burdens. The choice between intensive and 
nonintensive management also depends on other factors, 
including the patient’s functional status, comorbidities, and 
desires. A sequential single-agent strategy or an intermittent 
approach (combination therapy followed by maintenance) 
may minimize toxicity and be appropriate for patients who are 
not surgical candidates, irrespective of treatment response. 
Finally, the choice of second or further chemotherapy lines is 
closely related to the drugs used in prior-line treatment and 
has been shown to improve both PFS and OS.
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